Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
University Health Network, Toronto
Emory University
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Baylor College of Medicine
St. Jude Children's Research Hospital
University of Southern California
UNICANCER
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Seattle Children's Hospital
Seattle Children's Hospital
GlaxoSmithKline
Sarcoma Alliance for Research through Collaboration
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
UNICANCER
Memorial Sloan Kettering Cancer Center
Centre Leon Berard
Valo Therapeutics Oy
UNICANCER
Instituto do Cancer do Estado de São Paulo